Baird Reiterates an 'Outperform' on Pharmasset (VRUS); Raising PT On Our Top Mid-Cap Pick
Tweet Send to a Friend
Baird reiterates an 'Outperform' on Pharmasset (NASDAQ: VRUS), raises PT from $54 to $59.
Baird analyst says, "Continue to recommend ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "Continue to recommend ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
